中文

昊帆生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-24
ItemAmountY/Y
Revenue¥0.17B+27.2%
Gross profit¥0.06B
Operating income¥0.04B
Net income¥0.03B-6.0%
Gross margin35.5%Net margin 19.0%
Revenue Q/Q+2.6%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.11B64.5%
R&D¥0.01B6.2%
SG&A¥0.02B9.5%
Tax & other¥0.00B2.9%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

仁信新材宏景科技溯联股份星源卓镁英特科技华人健康安培龙协昌科技阿莱德波长光电世纪恒通森泰股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies